NLRP3 and age-related macular degeneration: Blocking pyroptosis by targeting the assembly of NLRP3 inflammasomes and GSDMD emerges as a potential therapeutic approach for addressing neuroinflammation and neurodegeneration-related conditions [70], including age-related macular degeneration (AMD) and Alzheimer’s disease [71].